Rxivist logo

Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants

By Shuo Du, Pulan Liu, Zhiying Zhang, Tianhe Xiao, Ayijiang Yasimayi, Weijin Huang, Youchun Wang, Yunlong Richard Cao, Xiaoliang Sunney Xie, Junyu Xiao

Posted 01 Aug 2021
bioRxiv DOI: 10.1101/2021.07.30.454402

The spread of the SARS-CoV-2 variants could seriously dampen the global effort to tackle the COVID-19 pandemic. Recently, we investigated the humoral antibody responses of SARS-CoV-2 convalescent patients and vaccinees towards circulating variants, and identified a panel of monoclonal antibodies (mAbs) that could efficiently neutralize the B.1.351 (Beta) variant. Here we investigate how these mAbs target the B.1.351 spike protein using cryo-electron microscopy. In particular, we show that two superpotent mAbs, BD-812 and BD-836, have non-overlapping epitopes on the receptor-binding domain (RBD) of spike. Both block the interaction between RBD and the ACE2 receptor; and importantly, both remain fully efficacious towards the B.1.617.1 (Kappa) and B.1.617.2 (Delta) variants. The BD-812/BD-836 pair could thus serve as an ideal antibody cocktail against the SARS-CoV-2 VOCs.

Download data

  • Downloaded 167 times
  • Download rankings, all-time:
    • Site-wide: 149,205
    • In biochemistry: 4,543
  • Year to date:
    • Site-wide: 70,789
  • Since beginning of last month:
    • Site-wide: 149,068

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide